TriangleNCT00036738 · STUDY IN CONTEXT
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogeno
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Number of patients with relapsed disease within 1 Year post-transplant. Relapse is defined as the detection of \> 5% blasts after a documented complete remission.
Number of patients surviving in CR up to five years post-transplant.
Number of patients surviving up to five years post-transplant.
Number of patients with TRM within 100 days post-transplant.
Number of patients with TRM within one year post-transplant.
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- trial label
- Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogeno
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 5
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0000
- source section id
- NCT00036738-om-0000
- source outcome index
- 0
- endpoint
- Relapse Free Survival
- endpoint definition
- Number of patients with relapsed disease within 1 Year post-transplant. Relapse is defined as the detection of \> 5% blasts after a documented complete remission.
- time origin
- Assessed up to 1 year
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0001
- source section id
- NCT00036738-om-0001
- source outcome index
- 1
- endpoint
- Leukemia-free Survival
- endpoint definition
- Number of patients surviving in CR up to five years post-transplant.
- time origin
- Assessed up to 5 years
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0002
- source section id
- NCT00036738-om-0002
- source outcome index
- 2
- endpoint
- Overall Survival
- endpoint definition
- Number of patients surviving up to five years post-transplant.
- time origin
- Assessed up to 5 years
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0003
- source section id
- NCT00036738-om-0003
- source outcome index
- 3
- endpoint
- Transplant-related Mortality
- endpoint definition
- Number of patients with TRM within 100 days post-transplant.
- time origin
- At day 100
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0004
- source section id
- NCT00036738-om-0004
- source outcome index
- 4
- endpoint
- Transplant-related Mortality
- endpoint definition
- Number of patients with TRM within one year post-transplant.
- time origin
- At 1 year
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Treatment (Allogeneic Nonmyeloablative HSCT)
- regimen
- See Detailed Description Cyclosporine: Given IV or PO Dasatinib: Given PO Fludarabine Phosphate: Given IV Imatinib Mesylate: Given PO Mycophenolate Mofetil: Given PO Nilotinib: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation Therapeutic Allogeneic Lymphocytes: Given IV Total-Body Irradiation: Undergo TBI
- analyzed count
- 28
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00036738-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Treatment (Allogeneic Nonmyeloablative HSCT)
- regimen
- See Detailed Description Cyclosporine: Given IV or PO Dasatinib: Given PO Fludarabine Phosphate: Given IV Imatinib Mesylate: Given PO Mycophenolate Mofetil: Given PO Nilotinib: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation Therapeutic Allogeneic Lymphocytes: Given IV Total-Body Irradiation: Undergo TBI
- analyzed count
- 28
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00036738-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0002
- arm key
- OG000
- arm label
- Treatment (Allogeneic Nonmyeloablative HSCT)
- regimen
- See Detailed Description Cyclosporine: Given IV or PO Dasatinib: Given PO Fludarabine Phosphate: Given IV Imatinib Mesylate: Given PO Mycophenolate Mofetil: Given PO Nilotinib: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation Therapeutic Allogeneic Lymphocytes: Given IV Total-Body Irradiation: Undergo TBI
- analyzed count
- 28
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00036738-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0003
- arm key
- OG000
- arm label
- Treatment (Allogeneic Nonmyeloablative HSCT)
- regimen
- See Detailed Description Cyclosporine: Given IV or PO Dasatinib: Given PO Fludarabine Phosphate: Given IV Imatinib Mesylate: Given PO Mycophenolate Mofetil: Given PO Nilotinib: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation Therapeutic Allogeneic Lymphocytes: Given IV Total-Body Irradiation: Undergo TBI
- analyzed count
- 28
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00036738-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- outcome key
- om-0004
- arm key
- OG000
- arm label
- Treatment (Allogeneic Nonmyeloablative HSCT)
- regimen
- See Detailed Description Cyclosporine: Given IV or PO Dasatinib: Given PO Fludarabine Phosphate: Given IV Imatinib Mesylate: Given PO Mycophenolate Mofetil: Given PO Nilotinib: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation Therapeutic Allogeneic Lymphocytes: Given IV Total-Body Irradiation: Undergo TBI
- analyzed count
- 28
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00036738-om-0004#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- nct id
- NCT00036738
- harm key
- EG000
- source section id
- NCT00036738-ae
- event group key
- EG000
- event group label
- Treatment (Allogeneic Nonmyeloablative HSCT)
- serious affected
- 2
- serious at risk
- 28
- other affected
- 8
- other at risk
- 28
- frequency threshold
- 0
- collection period
- AEs: Conditioning through Day 100; SAEs: Conditioning through Day 200
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice